| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
RMTI Stock Overview
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Rockwell Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.06 |
| 52 Week High | US$7.70 |
| 52 Week Low | US$1.17 |
| Beta | 1.21 |
| 1 Month Change | 68.85% |
| 3 Month Change | 5.10% |
| 1 Year Change | -69.34% |
| 3 Year Change | -92.45% |
| 5 Year Change | -97.18% |
| Change since IPO | -96.35% |
Recent News & Updates
Rockwell Medical Q2 Earnings Preview
Rockwell Medical (NASDAQ:RMTI) is scheduled to announce Q2 earnings results on Monday, August 15th, before market open. The consensus EPS Estimate is -$0.81 (-800.0% Y/Y) and the consensus Revenue Estimate is $16.8M (+11.0% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revision and 0 downward. Revenue estimates have seen 0 upward revision and 0 downward.
Shareholder Returns
| RMTI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 31.2% | 3.6% | 4.5% |
| 1Y | -69.3% | -20.7% | -8.9% |
Return vs Industry: RMTI underperformed the US Medical Equipment industry which returned -19.6% over the past year.
Return vs Market: RMTI underperformed the US Market which returned -9.6% over the past year.
Price Volatility
| RMTI volatility | |
|---|---|
| RMTI Average Weekly Movement | 14.4% |
| Medical Equipment Industry Average Movement | 9.4% |
| Market Average Movement | 7.6% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RMTI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: RMTI's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 300 | Mark Strobeck | https://www.rockwellmed.com |
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers.
Rockwell Medical, Inc. Fundamentals Summary
| RMTI fundamental statistics | |
|---|---|
| Market Cap | US$21.99m |
| Earnings (TTM) | -US$28.65m |
| Revenue (TTM) | US$66.13m |
0.3x
P/S Ratio-0.8x
P/E RatioIs RMTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RMTI income statement (TTM) | |
|---|---|
| Revenue | US$66.13m |
| Cost of Revenue | US$67.73m |
| Gross Profit | -US$1.60m |
| Other Expenses | US$27.05m |
| Earnings | -US$28.65m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.68 |
| Gross Margin | -2.42% |
| Net Profit Margin | -43.33% |
| Debt/Equity Ratio | 84.4% |
How did RMTI perform over the long term?
See historical performance and comparison